Edwards Lifesciences Corp (EW)vsBeyond Air Inc (XAIR)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
XAIR
Beyond Air Inc
$0.74
-1.08%
HEALTHCARE · Cap: $7.88M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 87531% more annual revenue ($6.07B vs $6.92M). EW leads profitability with a 17.7% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
XAIR
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Intrinsic value data unavailable for XAIR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Reasonable price relative to book value
Revenue surging 104.7% year-over-year
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -2.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : XAIR
The strongest argument for XAIR centers on Price/Book, Revenue Growth. Revenue growth of 104.7% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : XAIR
The primary concerns for XAIR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
EW profiles as a mature stock while XAIR is a hypergrowth play — different risk/reward profiles.
EW carries more volatility with a beta of 0.93 — expect wider price swings.
XAIR is growing revenue faster at 104.7% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 38/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Beyond Air Inc
HEALTHCARE · MEDICAL DEVICES · USA
Beyond Air, Inc., a clinical-stage biopharmaceutical and medical device company, develops nitric oxide (NO) generators and delivery systems. The company is headquartered in Garden City, New York.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?